CCRM Sits Down With Janet Rossant SickKids Research Institute

CCRM Sits Down With Janet Rossant

Dr. Janet Rossant, SickKids Research Institute, sits down with CCRM and shares her views on the current trends in regenerative medicine and how the potential for commercialization should factor into research plans. Dr. Rossant touches on her research for Cystic Fibrosis and on the changing culture in academia and the need to consider the clinical applications of research. She then explains how new discoveries can be turned into commercial products with the help of organizations like CCRM and the recently established Ontario Institute for Regenerative Medicine (OIRM).

CCRM Sits Down With Molly Shoichet University of Toronto

Molly Shoichet, University of Toronto

Dr. Molly Shoichet, University of Toronto, shares her perspective on discovery and commercialization of new therapies and tools in the regenerative medicine (RM) field. As the first Principal Investigator to be featured in CCRM’s Regenerative Medicine Leadership Series, Dr. Shoichet discusses her work, her take on what’s on the horizon for regenerative medicine and the relationship between academic labs and commercialization agents and how, working together, they can advance knowledge and see RM products make it to market. And if you’re interested, you can watch the previous two installments of the Regenerative Medicine Leadership Series.

CCRM Sits down with Michael D West CEO of BioTime

456610936_295

Dr. Michael West founded Geron Corporation and is CEO of BioTime Inc., which is focused on developing an array of research and therapeutic products using human embryonic stem cell technology. Dr. West is passionate about translating technologies from the test tubes to clinical applications and strongly advocates for pluripotent stem cells’ potential to revolutionize modern health care. He explains why in this video.

CCRM Sits Down with Stephen Minger

453999068_100

Dr. Stephen Minger is Global Head of Research and Development for the Cell Technologies business of GE Healthcare Life Sciences and, in this role, Dr. Minger travels the world to stay current and connected with what’s happening in the regenerative medicine industry. He shares his thoughts about the industry in this video.

Dr. Minger leads the development of GE Healthcare Life Sciences’ cell-based technologies for use in drug discovery and pharmaceutical research.  He also directs the development of GE Healthcare Life Sciences’ enabling technologies for the rapidly emerging field of regenerative medicine and cell therapy.

All other pages contact

For more information, please contact us.
Font Resize
Enable Contrast